Stay updated on Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.

Latest updates to the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6 on the page, indicating a new build of the site hosting the record. This update does not modify study details, eligibility criteria, or results and likely reflects a minor backend/UI improvement.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedPage revision changed from v3.6.4 to v3.6.5, indicating a small administrative update to the page. This update does not modify the study data or other visible content.SummaryDifference0.1%

- Check39 days agoChange DetectedAdds the updated document revision v3.6.4 for the study materials and removes the older v3.6.3 version. This reflects an updated protocol and related materials associated with the study on ClinicalTrials.gov.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision: v3.6.3 was added, indicating an updated version of the Study Protocol and Statistical Analysis Plan document. The previous revision (v3.6.2) was removed.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous Revision: v3.6.0. This reflects a software version update for the site rather than a change to study details.SummaryDifference0.1%

- Check82 days agoChange DetectedRecruitment status is updated to indicate no active enrollment. New help sections are added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment header is updated alongside a revision tag advancing to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.